314 related articles for article (PubMed ID: 26903268)
1. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.
Gupta M; Neavin D; Liu D; Biernacka J; Hall-Flavin D; Bobo WV; Frye MA; Skime M; Jenkins GD; Batzler A; Kalari K; Matson W; Bhasin SS; Zhu H; Mushiroda T; Nakamura Y; Kubo M; Wang L; Kaddurah-Daouk R; Weinshilboum RM
Mol Psychiatry; 2016 Dec; 21(12):1717-1725. PubMed ID: 26903268
[TBL] [Abstract][Full Text] [Related]
2. Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction.
Nguyen TTL; Liu D; Ho MF; Athreya AP; Weinshilboum R
Front Pharmacol; 2020; 11():614048. PubMed ID: 33510640
[TBL] [Abstract][Full Text] [Related]
3. Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics.
Abo R; Hebbring S; Ji Y; Zhu H; Zeng ZB; Batzler A; Jenkins GD; Biernacka J; Snyder K; Drews M; Fiehn O; Fridley B; Schaid D; Kamatani N; Nakamura Y; Kubo M; Mushiroda T; Kaddurah-Daouk R; Mrazek DA; Weinshilboum RM
Pharmacogenet Genomics; 2012 Apr; 22(4):247-53. PubMed ID: 22322242
[TBL] [Abstract][Full Text] [Related]
4. TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response.
Ho MF; Zhang C; Zhang L; Wei L; Zhou Y; Moon I; Geske JR; Choi DS; Biernacka J; Frye M; Wen Z; Karpyak VM; Li H; Weinshilboum R
Mol Psychiatry; 2021 Jul; 26(7):3122-3133. PubMed ID: 32753686
[TBL] [Abstract][Full Text] [Related]
5. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.
Ji Y; Hebbring S; Zhu H; Jenkins GD; Biernacka J; Snyder K; Drews M; Fiehn O; Zeng Z; Schaid D; Mrazek DA; Kaddurah-Daouk R; Weinshilboum RM
Clin Pharmacol Ther; 2011 Jan; 89(1):97-104. PubMed ID: 21107318
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.
Athreya AP; Neavin D; Carrillo-Roa T; Skime M; Biernacka J; Frye MA; Rush AJ; Wang L; Binder EB; Iyer RK; Weinshilboum RM; Bobo WV
Clin Pharmacol Ther; 2019 Oct; 106(4):855-865. PubMed ID: 31012492
[TBL] [Abstract][Full Text] [Related]
7. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
Ji Y; Schaid DJ; Desta Z; Kubo M; Batzler AJ; Snyder K; Mushiroda T; Kamatani N; Ogburn E; Hall-Flavin D; Flockhart D; Nakamura Y; Mrazek DA; Weinshilboum RM
Br J Clin Pharmacol; 2014 Aug; 78(2):373-83. PubMed ID: 24528284
[TBL] [Abstract][Full Text] [Related]
8. ERICH3: vesicular association and antidepressant treatment response.
Liu D; Zhuang Y; Zhang L; Gao H; Neavin D; Carrillo-Roa T; Wang Y; Yu J; Qin S; Kim DC; Liu E; Nguyen TTL; Biernacka JM; Kaddurah-Daouk R; Dunlop BW; Craighead WE; Mayberg HS; Binder EB; Frye MA; Wang L; Weinshilboum RM
Mol Psychiatry; 2021 Jun; 26(6):2415-2428. PubMed ID: 33230203
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.
Ji Y; Biernacka JM; Hebbring S; Chai Y; Jenkins GD; Batzler A; Snyder KA; Drews MS; Desta Z; Flockhart D; Mushiroda T; Kubo M; Nakamura Y; Kamatani N; Schaid D; Weinshilboum RM; Mrazek DA
Pharmacogenomics J; 2013 Oct; 13(5):456-63. PubMed ID: 22907730
[TBL] [Abstract][Full Text] [Related]
10. The ERICH3 rs11580409 polymorphism is associated with 6-month antidepressant response in depressed patients.
Chappell K; Colle R; Ait Tayeb AEK; Bouligand J; El-Asmar K; Deflesselle E; Fève B; Becquemont L; Corruble E; Verstuyft C
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Dec; 119():110608. PubMed ID: 35878676
[TBL] [Abstract][Full Text] [Related]
11. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.
Ji Y; Biernacka J; Snyder K; Drews M; Pelleymounter LL; Colby C; Wang L; Mrazek DA; Weinshilboum RM
Pharmacogenomics J; 2012 Feb; 12(1):78-85. PubMed ID: 20877297
[TBL] [Abstract][Full Text] [Related]
12. A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder.
Ren S; Peng H; Zhang J; Yang J; He Y; Sun Z; Wang G
Gene; 2024 Oct; 926():148596. PubMed ID: 38782219
[TBL] [Abstract][Full Text] [Related]
13. Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.
Qin S; Eugene AR; Liu D; Zhang L; Neavin D; Biernacka JM; Yu J; Weinshilboum RM; Wang L
Clin Pharmacol Ther; 2020 Mar; 107(3):662-670. PubMed ID: 31628858
[TBL] [Abstract][Full Text] [Related]
14. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.
Masiran R; Sidi H; Mohamed Z; Mohd Nazree NE; Nik Jaafar NR; Midin M; Das S; Mohamed Saini S
J Sex Med; 2014 Apr; 11(4):1047-1055. PubMed ID: 24533444
[TBL] [Abstract][Full Text] [Related]
15. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.
Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A
J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644
[TBL] [Abstract][Full Text] [Related]
16. Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk.
Srivastava A; Singh P; Gupta H; Kaur H; Kanojia N; Guin D; Sood M; Chadda RK; Yadav J; Vohora D; Saso L; Kukreti R
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018568
[TBL] [Abstract][Full Text] [Related]
17. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder.
Illi A; Setälä-Soikkeli E; Kampman O; Viikki M; Nuolivirta T; Poutanen O; Huhtala H; Mononen N; Lehtimäki T; Leinonen E
Psychiatry Res; 2010 Mar; 176(1):85-7. PubMed ID: 20071037
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
[TBL] [Abstract][Full Text] [Related]
19. Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder.
Paroni G; Seripa D; Fontana A; D'Onofrio G; Gravina C; Urbano M; Addante F; Lozupone M; Copetti M; Pilotto A; Greco A; Panza F
Mol Neurobiol; 2017 Mar; 54(2):1340-1351. PubMed ID: 26843110
[TBL] [Abstract][Full Text] [Related]
20. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
Knorr UB
Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
